- Product Name:
- R.D. 1403
- rac Sulpiride
- Product Categories:
- Dopamine receptor
- Intermediates & Fine Chemicals
- Mol File:
Sulpiride Chemical Properties
- Melting point:
- D25 -66.8° (c = 0.5 in DMF)
- 1.2375 (rough estimate)
- refractive index
- 1.6320 (estimate)
- storage temp.
- 45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 8.0 mg/mL
- pKa1 9.00, pKa2 10.19(at 25℃)
- Water Solubility
- <0.21g/L(25 ºC)
- CAS DataBase Reference
- 15676-16-1(CAS DataBase Reference)
- NIST Chemistry Reference
- EPA Substance Registry System
- Sulpiride (15676-16-1)
- Language:English Provider:5-(Aminosufonyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxybenzamide
- Language:English Provider:SigmaAldrich
Sulpiride Usage And Synthesis
Sulpiride is White Solid
Sulpiride is an antipsychotic drug used in the treatment of Schozophrenia and depression.
dopamine receptor antagonist, antipsychotic
Sulpiride possesses moderate neuroleptic activity along with some stimulating and antidepressant effects. It has antiemetic, moderately cataleptogenic, and antiserotonin action. It facilitates increased blood flow in the stomach. It speeds up the restorative processes in tissues. It is used for schizophrenia, depression, migraines, disturbance of behavioral functions, and stomach and duodenal ulcers.
Sulpiride is a member of the class of benzamides obtained from formal condensation between the carboxy group of 2-methoxy-5-sulfamoylbenzoic acid and the primary amino group of (1-ethylpyrrolidin-2-yl)methylamine.
1-Ethyl-2-aminomethylpyrrolidine is reacted with 2-methoxy-5- sulfamoylbenzoic acid to give sulpiride.
Dogmatyl (Laboratoires Delagrange, France).
Tranquilizer, Digestive aid
Standard D 2 -like dopamine receptor antagonist.
(±)-Sulpiride is a D2 dopamine antagonist and an effective treatment for schizophrenia when used in combination with clozapine, a relatively weak D2-dopaminergic antagonist. It is an antipsychotic agent and also exhibits neuroleptic properties but poorly penetrates the central nervous system.45,46
Acute and chronic schizophrenia
Sulpiride, N-[(1-ethyl-2-pirrolidinylmethyl]-5-sulfamoyl-O-anizamide (6.7.2), is synthesized from 5-aminosulfosalycilic acid. Methylating this with dimethylsulfate gives 2-methoxy-5-aminosulfonylbenzoic acid (6.7.1), which is transformed into an amide using 2-aminomethyl-1-ethylpyrrolidine as amine components and carbonyl-1,1′-bisimidazole as a condensing agent [70–74].
Potentially hazardous interactions with other drugs
Anaesthetics: enhanced hypotensive effect.
Analgesics: increased risk of convulsions with tramadol; enhanced hypotensive and sedativeeffects with opioids; increased risk of ventricular arrhythmias with methadone.
Anti-arrhythmics increased risk of ventricular arrhythmias with anti-arrhythmics that prolong the QT interval, e.g. procainamide, disopyramide and amiodarone - avoid with amiodarone.
Antibacterials: increased risk of ventricular arrhythmias with moxifloxacin and parenteral erythromycin - avoid with moxifloxacin.
Antidepressants: possibly increased risk of ventricular arrhythmias and antimuscarinic side effects with tricyclics - avoid.
Antiepileptics: antagonism (convulsive threshold lowered).
Antimalarials: avoid with artemether/lumefantrine.
Antipsychotics: increased risk of ventricular arrhythmias with droperidol, haloperidol and pimozide - avoid; possible increased risk of ventricular arrhythmias with risperidone.
Antivirals: concentration possibly increased by ritonavir.
Anxiolytics and hypnotics: increased sedative effects.
Atomoxetine: increased risk of ventricular arrhythmias.
Beta-blockers: enhanced hypotensive effect; increased risk of ventricular arrhythmias with sotalol.
Cytotoxics: increased risk of ventricular arrhythmias with vandetanib - avoid; increased risk of ventricular arrhythmias with arsenic trioxide.
Diuretics: enhanced hypotensive effect.
Lithium: increased risk of extrapyramidal side effects and possibly neurotoxicity.
Pentamidine: increased risk of ventricular arrhythmias.
Sulpiride undergoes little metabolism.
95% of a dose is excreted in the urine and faeces, mainly as unchanged drug.
- 010-82848833 400-666-7788
- 821-50328103-801 18930552037
- +86 (0) 571 85 58 67 18